Europe Neoantigens Market Share and Forecast by 2028

The neoantigens market in Europe is expected to grow from US$ 86,165.00 thousand in 2023 to US$ 341,855.35 thousand by 2028; it is estimated to grow at a CAGR of 31.7% from 2023 to 2028.

The UK, Germany, and France are major economies in Europe. Evolution in neoantigen vaccines against cancer is the major factor driving the growth of the Europe neoantigens market. Developments in biotechnology have led to rise in acceptance for immunotherapy, further driving its use in personalized medicines. Immunotherapy is widely used to treat cancer; a few the immunotherapy procedures involve the use of neoantigens, the antigens present on the surface of cancer cells. Therefore, applications of neoantigens are being widely studied to treat cancer. The uniqueness of neoantigens allows researchers to identify patients’ immune system and find antigens to target cancer cells without disturbing healthy cells. The developments in immunotherapy caught pace after 2015, when the first clinical trial of neoantigen vaccine was performed. In 2017, two additional clinical trial studies were published by Neon Therapeutics that proved the efficacy of neoantigen vaccine treat melanoma (skin cancer) in humans. The positive results of clinical trials have attracted various startups to discover and develop neoantigen-based cancer therapeutics. Many companies have shown interest in the development of neoantigens. Following are few examples of companies involved in the development of neoantigens.

•   BioNTech SE is a German company operating in the neoantigen vaccines market. BioNTech SE has developed Individualized Vaccines Against Cancer (IVAC) Mutanome platform that engineer RNA molecules to produce customized neoantigen vaccine. The clinical trials for IVAC that target triple negative breast cancer, multiple tumor types, and melanoma are pending.

•   The ATLAS platform of Genocea Biosciences uses an ex-vivo method to develop neoantigen vaccines. Genocea Biosciences has raised ~US$ 91 million funds from investors such as Polaris Partners, GlaxoSmithKline, and Johnson & Johnson Innovation to develop its neoantigen cancer vaccine—GEN-009. Currently in the Phase 1a/2 clinical trial, the vaccine is designed to treat melanoma, lung cancer, and carcinomas.

•   Gritstone Oncology uses its AI platform—EDGE—to develop neoantigen vaccines using an in-silico approach. The company has developed two products GRANITE-001 and SLATE-001. GRANITE-001 is designed as an individual treatment based on patient’s specific tumor type, whereas SLATE-001 is formulated as a common neoantigen vaccine that can be used for multiple patients showing similar neoantigen.

•   Agenus Inc. has developed AutoSynVax (ASV) neoantigen vaccine that is administered with an adjuvant QS-21 Stimulon to treat solid tumors. At present ASV is in the Phase 1 clinical trial in USA.

•   Since 2016, Moderna, Inc. is involved in clinical trials for its personalized cancer vaccine (PCV) mRNA-4157 in combination with Keytruda by Merck. In November 2020, Moderna, Inc. published updates about its cancer vaccines stating that administrating mRNA-4157 in combination with Keytruda is well tolerated at all dose levels and has produced responses in patients.

Such developments in the neoantigen vaccines against cancer are fueling the market growth.

In Europe, there is an exponential growth of COVID-19 cases. Spain, Italy, Germany, France, and the UK are among the most affected European countries. As per the Worldometer, as of May 6th, 2020, Spain, the UK, Italy, Germany, and France recorded 3,551,262; 4,425,940; 4,070,400; 3,469,448; and 5,706,378, COVID-19 cases, respectively, and the deaths toll is also high in these countries. As per the news article, due to COVID-19 emergency, access to chemotherapy, scans, transplants, and surgery has become difficult for thousands of cancer patients in Italy. According to the research led by Codice Viola, charity that supports pancreatic cancer patients found that more than 500 breast or pancreatic patients’ appointments for chemotherapy or radiotherapy were postponed. Additionally, 64% of surgical procedures were postponed and more than half of the follow-up appointments rescheduled. Additionally, in Europe, many of the cancer vaccine development companies have been directed to develop COVID-19 vaccine. For instance, on April 2020, NEC announced that, after its neoantigen cancer vaccine project, it is planning to develop COVID-19 vaccine using AI with a close collaboration with NOI, a biotechnology subsidiary located in Oslo, Norway. Also, patient enrollment in clinical trials has been significantly declined. These factors are likely to have negative impact on the market growth.

Europe Neoantigens Market Segmentation

Europe Neoantigens Market – By Treatment

• Combination Therapy
• Mono Therapy

Europe Neoantigens Market – By Therapeutic Specialty

• Gastrointestinal Cancer
• Lung Cancer
• Solid Tumors
• Urinary System Cancers
• Melanoma
• Head and Neck Cancer
• Others

Europe Neoantigens Market– By Country

• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe

Europe Neoantigens Market-Companies Mentioned

• Achilles Therapeutics plc
• Frame Cancer Therapeutics
• Genocea
• Immunicum AB
• Medigene AG
• Moderna, Inc

Europe Neoantigens Report Scope